Telix Pharmaceuticals Limited
TLXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Telix Pharmaceuticals Limited focuses on Biotechnology services and products. Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. With a market capitalization of $3.10B, it sits in mid-cap territory. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Market Cap
$3.10B
Beta
0.56
P/E (TTM)
91.50
P/E (Fwd)
-371.93
EPS (TTM)
$0.10
EPS (Fwd)
$-0.02
ROE
7.4%
ROA
2.7%
Cash
$251.9M
Total Debt
$579.9M
Free CF
-$62.6M
52W Change
-15.4%
Annual Financials
Cash vs Debt
Where TLX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TLX finished 0.94% above its 150-day moving average ($10.64) and 9.37% above its 200-day moving average ($9.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TLX overbought or oversold?
At the October 20, 2026 close, TLX's RSI(14) was 39.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, TLX has $251.9M in cash with $579.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$62.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 7.4% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $108.9M (2022) to $803.8M (2025), reflecting a 638% increase over the period.
The relatively low beta of 0.56 suggests TLX is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing TLX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.